American Academy of Dermatology Annual Meeting

One-Year Data Reinforces Icotyde’s Position as Transformative Psoriasis Therapy: Sustained Clearance and Favorable Safety Profile

Post author:Bree Clare
Post published:April 24, 2026
Post category:Psoriasis

Johnson & Johnson announced promising long-term efficacy and safety data for Icotyde (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor for plaque psoriasis treatment.…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More